{"product_id":"tlsa-vrio-analysis","title":"Tiziana Life Sciences Ltd (TLSA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Tiziana Life Sciences Ltd (TLSA)'s enduring success starts here: this VRIO analysis cuts straight to the chase, evaluating the Value, Rarity, Inimitability, and Organization of its core assets to pinpoint its true competitive advantage. Discover immediately whether Tiziana Life Sciences Ltd (TLSA) possesses resources that are truly difficult for rivals to copy and why they matter - read on below to see the full breakdown.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Intranasal Foralumab (Lead Drug Candidate)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Tiziana Life Sciences Ltd (TLSA) Intranasal Foralumab, and the core takeaway is this: the nasal delivery of this specific anti-CD3 antibody creates a unique, though likely temporary, competitive edge in the neuroinflammation space.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Novel Delivery for a Known Target\u003c\/h3\u003e\n\u003cp\u003eThe value proposition hinges on the delivery method. Intranasal Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development using the nasal route. This non-systemic approach aims to stimulate regulatory T cells for immune tolerance while avoiding the systemic immune suppression often associated with intravenous (IV) delivery, which is a major plus for chronic neuroinflammatory diseases.\u003c\/p\u003e\n\u003cp\u003eConsider the ongoing Phase IIa trial (NCT06292923) for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Preliminary data from 10 patients in the Expanded Access Program showed stability or improvement in all treated participants over 6 months. This suggests the mechanism is delivering tangible, albeit early, patient benefit.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Unique Combination\u003c\/h3\u003e\n\u003cp\u003eRarity is high here because of the specific combination: a fully human anti-CD3 mAb delivered intranasally. While anti-CD3 is known, this specific route for this molecule in these indications is currently unmatched in the clinical landscape. It’s a distinct platform advantage right now.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier, Not Impossible\u003c\/h3\u003e\n\u003cp\u003eReplicating the exact progress - navigating the regulatory pathway and generating the specific clinical data - is difficult and time-consuming, giving TLSA a buffer. However, the core molecule concept (anti-CD3) is not proprietary in the broader sense. Competitors could pursue similar targets or delivery methods, making the advantage less than fully sustainable. It’s a medium-to-high barrier to entry, not an impenetrable fortress.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Execution Amidst Financial Strain\u003c\/h3\u003e\n\u003cp\u003eThe organization appears highly focused on this asset. Evidence of this focus includes the progression of the na-SPMS Phase II trial, which Tiziana expects to conclude its blinded portion by the end of 2025. Furthermore, the recent acceptance of the ALS Phase 2 trial into the Healey ALS MyMatch Program on November 25, 2025, shows active pipeline expansion. To be fair, the financial footing requires attention; the company reported a total comprehensive loss of \\$5.3 million for the first half of 2025, though cash on hand stood at \\$7.3 million as of June 30, 2025. They need to manage that burn rate.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eThe current advantage is best classified as \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e. The first-mover status in this specific nasal\/anti-CD3 combination is potent, but it lasts only until a competitor successfully reads out positive data from their own Phase II or III trials in a similar indication. If the na-SPMS data is strong, that advantage extends.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick summary of the VRIO scoring for the Intranasal Foralumab platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eScore (1-4)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eNovel nasal delivery for neuroinflammation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eSole fully human anti-CD3 mAb in this delivery method\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh cost\/time to replicate clinical data, but core concept known\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eFocused on clinical execution across MS, MSA, and ALS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey supporting facts for this analysis:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe na-SPMS trial involves 54 planned patients.\u003c\/li\u003e\n\u003cli\u003eThe EAP for MS showed stability\/improvement in all 14 treated patients in 6 months.\u003c\/li\u003e\n\u003cli\u003eThe company reported \\$7.3 million in cash as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe drug is being studied in ALS, MSA, and na-SPMS.\u003c\/li\u003e\n\u003cli\u003eThe blinded MS trial is expected to finish by the end of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft a 13-week cash flow projection incorporating the \\$2 million raised post-June 30, 2025, by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Proprietary Nasal Drug Delivery Technology (IP Platform)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eProprietary Nasal Drug Delivery Technology (IP Platform)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This platform technology enables alternative immunotherapy routes, which could be applied across multiple future drug candidates beyond Foralumab. Intranasal foralumab, the lead candidate, is being developed for non-active Secondary Progressive Multiple Sclerosis (SPMS), Multiple System Atrophy (MSA), and Alzheimer's disease.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; patented technology for alternative, non-invasive delivery of biologics like mAbs is a significant barrier to entry. The technology for alternative routes of immunotherapy has been patented with several applications pending.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the patents covering formulation and manufacturing processes are legally protected, making direct imitation difficult. Specific formulation criteria are detailed in patent filings.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Medium; the company is actively leveraging it (e.g., planning to spin out the IL-6 asset), showing organizational intent to exploit the platform. The company reported $7.3 million in cash as of June 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; strong, broad patent protection on a novel delivery method provides a long-term moat.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eQuantification\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Scope\u003c\/td\u003e\n\u003ctd\u003eProtection Duration\u003c\/td\u003e\n\u003ctd\u003ePatent protected until 2040 for intranasal Foralumab\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulation Specificity\u003c\/td\u003e\n\u003ctd\u003eProtein Concentration\u003c\/td\u003e\n\u003ctd\u003eMust be at least 90% of the starting concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulation Specificity\u003c\/td\u003e\n\u003ctd\u003epH Stability\u003c\/td\u003e\n\u003ctd\u003eMust maintain a $\\text{pH}$ of $5.5 \\pm 0.2$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Device\u003c\/td\u003e\n\u003ctd\u003eDose Volume\u003c\/td\u003e\n\u003ctd\u003eMust deliver a 100 µL dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganizational Action\u003c\/td\u003e\n\u003ctd\u003eAsset Strategy\u003c\/td\u003e\n\u003ctd\u003eIntention to spin out the anti-IL-6 receptor monoclonal antibody (TZLS-501) asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe platform's application scope is demonstrated by ongoing clinical development in multiple indications:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIntranasal Foralumab Phase 2a trial for non-active SPMS (Expanded Access Program ($\\text{n}=10$))\u003c\/li\u003e\n\u003cli\u003ePhase 2 trial for Multiple System Atrophy (MSA) with dosing commenced in August 2025\u003c\/li\u003e\n\u003cli\u003ePhase 2 Clinical Trial planned for Mild Alzheimer's Disease in 2H 2025\u003c\/li\u003e\n\u003cli\u003ePhase 2 Clinical Trial planned for ALS to begin 2H 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Broad Neurodegenerative\/Neuroinflammatory Pipeline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Diversifies risk away from a single indication; includes na-SPMS, MSA (dosing started August 2025), Alzheimer's, and ALS candidates.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition is anchored in the breadth of the neurodegenerative\/neuroinflammatory pipeline, centered on the lead asset, intranasal Foralumab, a fully human anti-CD3 monoclonal antibody with patent protection extending until \u003cstrong\u003e2040\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eLead Asset\u003c\/th\u003e\n\u003cth\u003eCurrent\/Planned Trial Phase \u0026amp; Status\u003c\/th\u003e\n\u003cth\u003eKey Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Active SPMS\u003c\/td\u003e\n\u003ctd\u003eIntranasal Foralumab\u003c\/td\u003e\n\u003ctd\u003ePhase 2a began in 4Q 2023 (Expanded Access Program, n=\u003cstrong\u003e10\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e of na-SPMS EA patients showed improvement or stability within 6 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiple System Atrophy (MSA)\u003c\/td\u003e\n\u003ctd\u003eIntranasal Foralumab\u003c\/td\u003e\n\u003ctd\u003ePhase 2a dosing commenced in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eFDA approved IND for Phase 2a trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMild Alzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003eIntranasal Foralumab\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Clinical Trial to Begin \u003cstrong\u003e2H 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eOngoing Expanded Access Program (EAP) for Moderate Alzheimer's Disease began dosing in December 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmyotrophic Lateral Sclerosis (ALS)\u003c\/td\u003e\n\u003ctd\u003eIntranasal Foralumab\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Trial to Begin \u003cstrong\u003e2H 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eTrial accepted into the Healey ALS MyMatch Program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Medium; many biotechs focus on one area, but TLSA's breadth in CNS\/inflammation is notable for its size.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIntranasal Foralumab is noted as the \u003cstrong\u003esole\u003c\/strong\u003e fully human anti-CD3 monoclonal antibody currently undergoing clinical development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Medium; competitors can pursue similar indications, but replicating the specific clinical trial status across all these areas takes time and capital.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has multiple trials underway or planned, with expected readouts from these studies by the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; management is clearly directing resources across these indications, showing a structured development plan.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFinancial data reflects resource allocation priorities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal comprehensive loss for the six months ended June 30, 2025, was \u003cstrong\u003e$5.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash on hand as of June 30, 2025, was \u003cstrong\u003e$7.3 million\u003c\/strong\u003e, with an additional \u003cstrong\u003e$2 million\u003c\/strong\u003e raised post-period end.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization as of December 7, 2025, was \u003cstrong\u003e$206.75M\u003c\/strong\u003e, with \u003cstrong\u003e118.82M\u003c\/strong\u003e Shares Outstanding.\u003c\/li\u003e\n\u003cli\u003eOther receivables stood at \u003cstrong\u003e$5.3 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; the value is contingent on positive data from the multiple ongoing trials; success in one area validates the others.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is contingent upon achieving positive clinical outcomes, such as the stability or improvement seen in \u003cstrong\u003e100%\u003c\/strong\u003e of the initial \u003cstrong\u003e10\u003c\/strong\u003e na-SPMS Expanded Access Program patients within 6 months.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Issued and Pending Worldwide Patents\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides legal exclusivity for composition of matter, formulation, and manufacturing, securing future revenue streams. Foralumab is explicitly mentioned as being 'patent protected until \u003cstrong\u003e2040\u003c\/strong\u003e' for multiple administration routes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; most clinical-stage biotechs have IP, but the worldwide scope covering multiple aspects is a strong asset. The company's technology for alternative routes of immunotherapy has been patented with several applications pending.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patent law creates a high barrier; competitors must design around existing claims. Specific granted US patents include \u003cstrong\u003eNo. 10,759,858\u003c\/strong\u003e and \u003cstrong\u003eNo. 10,688,186\u003c\/strong\u003e, which cover composition-of-matter and use for anti-CD3 mAbs like Foralumab.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company actively mentions its patent portfolio as a foundation for its pipeline applications. A new patent application was filed on \u003cstrong\u003eJanuary 5, 2024\u003c\/strong\u003e, relating to the combination of Foralumab with a GLP-1 Receptor Agonist.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; patents offer the longest-lasting protection in the pharmaceutical industry.\u003c\/p\u003e\n\n\u003cp\u003eThe intellectual property portfolio supports key clinical assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIntranasal \u003cstrong\u003eForalumab\u003c\/strong\u003e (TZLS-401) patent protection extending until \u003cstrong\u003e2040\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePatents covering proprietary technologies on \u003cstrong\u003eoral and nasal administration\u003c\/strong\u003e of anti-CD3 mAbs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eA patent application filed on \u003cstrong\u003eJanuary 5, 2024\u003c\/strong\u003e, for combination therapy of Foralumab with GLP-1 Receptor Agonist for obesity-associated inflammation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey Examples of Granted Intellectual Property:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Aspect\u003c\/th\u003e\n\u003cth\u003ePatent Number (Example)\u003c\/th\u003e\n\u003cth\u003eAsset\/Use Covered\u003c\/th\u003e\n\u003cth\u003eGrant Date (Example)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposition of Matter\/Use\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo. 10,759,858\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMethods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn's Disease\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 18, 2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposition of Matter\/Use\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo. 10,688,186\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOral administration of anti-CD3 mAbs for treatment of human diseases\u003c\/td\u003e\n\u003ctd\u003ePrior to \u003cstrong\u003eAugust 18, 2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending Application\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003ctd\u003eCombination of Foralumab with GLP-1 Receptor Agonist\u003c\/td\u003e\n\u003ctd\u003eFiled \u003cstrong\u003eJanuary 5, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Experienced Executive Team (Management Capital)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Brings necessary expertise in drug development and commercialization, crucial for navigating FDA\/EMA processes and investor relations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many small biotechs have experienced leaders, but the specific mix of commercial and clinical expertise matters.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; key individuals are hard to poach, but a competitor could hire a similarly experienced team over time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; evidenced by successful navigation of Nasdaq compliance and active conference participation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while valuable, key personnel can leave, making this advantage less durable than IP.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Observation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTeam possesses extensive drug development and commercialization experience.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eSpecific mix of expertise is not universally common among small biotechs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eKey personnel retention risk exists.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eRegained compliance with Nasdaq minimum bid price requirement on \u003cstrong\u003eMarch 12, 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Total compensation: \u003cstrong\u003eUS$4.7m\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCEO tenure: \u003cstrong\u003e1.3yrs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eManagement average tenure: \u003cstrong\u003e1.9yrs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBoard average tenure: \u003cstrong\u003e9.9yrs\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAppointment of Chief Development Officer, William A. Clementi, effective \u003cstrong\u003eSeptember 1, 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganizational Milestones Related to Management Execution:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRegained compliance with Nasdaq listing minimum bid price rule after failing to meet the $1.00 closing bid price for 30 consecutive business days starting around \u003cstrong\u003eJanuary 29, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompany reported Pretax Income (Earnings) of \u003cstrong\u003e-A$25.93 Million\u003c\/strong\u003e for the year ended 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Clinical Validation in Multiple Indications\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates the platform's potential across different diseases, significantly de-risking the asset in the eyes of potential partners or acquirers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; having multiple advanced programs active simultaneously is a sign of operational capability for a company with a market capitalization of \u003cstrong\u003e$203.31 million\u003c\/strong\u003e as of December 5, 2025, with approximately \u003cstrong\u003e116.85 million\u003c\/strong\u003e shares in issue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\/Key Event\u003c\/th\u003e\n\u003cth\u003ePatient Count\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Active SPMS (na-SPMS)\u003c\/td\u003e\n\u003ctd\u003ePhase 2a Trial (NCT06292923) \u0026amp; Expanded Access (EA) Program (NCT06802328)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 patients\u003c\/strong\u003e dosed in EA; FDA allowed \u003cstrong\u003e20 additional patients\u003c\/strong\u003e for EA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiple System Atrophy (MSA)\u003c\/td\u003e\n\u003ctd\u003ePhase 2a Study IND Approved; First Patient Dosed\u003c\/td\u003e\n\u003ctd\u003eFirst patient dosed in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e; Open-label, \u003cstrong\u003esix-month\u003c\/strong\u003e study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmyotrophic Lateral Sclerosis (ALS)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 IND Submitted; Grant Secured\u003c\/td\u003e\n\u003ctd\u003ePlanned trial size of \u003cstrong\u003e20 patients\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003ePipeline Candidate\u003c\/td\u003e\n\u003ctd\u003ePart of the three neurodegenerative diseases focus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors cannot easily replicate the clinical data already generated in na-SPMS or the August 2025 MSA dosing start.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ena-SPMS Expanded Access Program reported either \u003cstrong\u003eimprovement or stability of disease seen within 6 months in all 10 patients\u003c\/strong\u003e dosed to date.\u003c\/li\u003e\n\u003cli\u003eThe intranasal foralumab Phase II trial for na-SPMS began subject screening in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Multiple System Atrophy (MSA) Phase 2a study commenced dosing in \u003cstrong\u003eAugust 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the team is managing complex, simultaneous trials, including securing a grant for the ALS trial.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe ALS Association awarded a grant to support a small, early-stage clinical trial testing foralumab nasal spray for ALS.\u003c\/li\u003e\n\u003cli\u003eThe ALS trial grant is awarded as part of the Hoffman ALS Clinical Trial Awards Program.\u003c\/li\u003e\n\u003cli\u003eThe planned ALS Phase 2 trial will involve \u003cstrong\u003e20 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; historical clinical data is a sunk cost that cannot be easily replicated by rivals.\u003c\/p\u003e\n\u003cp\u003eIntranasal foralumab is noted as the \u003cstrong\u003eonly fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Strategic Partnership\/Collaboration Framework\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic Partnership\/Collaboration Framework\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows TLSA to accelerate development or commercialization without immediately depleting its cash reserves, which stood at \u003cstrong\u003e$7.3 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; most biotechs seek partnerships, but TLSA's success in securing high-profile invitations (like the Riyadh Forum) suggests strong networking.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; the relationships are hard to copy, but the strategy of seeking partnerships is common.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Medium; the company explicitly states this is a key part of its growth strategy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; depends on the quality and success of the current relationships being cultivated.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Reserves (as of date provided)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey CDMO Partnership Announced\u003c\/td\u003e\n\u003ctd\u003eAgreement with Renaissance Lakewood LLC\u003c\/td\u003e\n\u003ctd\u003eFebruary 21, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFocus of CDMO Partnership\u003c\/td\u003e\n\u003ctd\u003eOptimize formulation and scale-up of intranasal foralumab\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIL-6 Pathway Transaction Benchmark\u003c\/td\u003e\n\u003ctd\u003eNovartis acquisition of Tourmaline Bio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Candidate in Clinical Development\u003c\/td\u003e\n\u003ctd\u003eIntranasal foralumab (fully human anti-CD3 mAb)\u003c\/td\u003e\n\u003ctd\u003eOngoing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's active engagement in external forums and programs underscores the organizational commitment to this framework:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTLSA was invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Riyadh, Saudi Arabia, on \u003cstrong\u003eOctober 1–2, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eManagement was scheduled to present at BIO-Europe in Vienna from \u003cstrong\u003eNovember 3–5, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTLSA was scheduled to present at the Jefferies London Healthcare Conference on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe intranasal foralumab Phase 2 Clinical Trial was accepted into the Healey ALS MyMatch Program on \u003cstrong\u003eNovember 25, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: Cash Position and Financial Strategy\n\u003c\/h2\u003e\n\u003ch\u003eCash Position and Financial Strategy\u003c\/h\u003e\n\u003cp\u003e\nValue: The decision in January 2025 not to raise capital immediately suggests management believes current cash can fund near-term milestones, preserving shareholder equity from dilution.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Low; cash on hand is common, but the strategic choice to avoid dilution when facing operational burn, as evidenced by negative TTM revenue figures, is a specific management decision.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low; this is a financial decision, not a structural asset; competitors can adopt the same stance.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Medium; the decision shows a clear, albeit risky, financial strategy to manage burn rate.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: None; this is a necessary operational function, not a source of advantage unless the cash position is vastly superior to peers.\n\u003c\/p\u003e\n\u003cp\u003e\nKey Financial Metrics for Context:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Period\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short Term Investments (Total Cash)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.25M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMost Recent Quarter (MRQ)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.72 Million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.60M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.40M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt \/ Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMRQ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (TTM)\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e-$18.46M\u003c\/strong\u003e and \u003cstrong\u003e-$12.84M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTrailing Twelve Months (TTM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecasted Return on Equity (ROE)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-260.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eForecasted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nDetails of Recent Financing Strategy:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nIntention announced on January 23, 2025, not to engage in capital raising activities for the immediate future.\n\u003c\/li\u003e\n\u003cli\u003e\nThis decision followed the discovery of new immune biomarkers in na-SPMS patients treated with nasal foralumab.\n\u003c\/li\u003e\n\u003cli\u003e\nThe company previously entered a registered direct offering in October 2024 for up to approximately \u003cstrong\u003e$10 Million\u003c\/strong\u003e gross proceeds, with an initial funding of approximately \u003cstrong\u003e$5 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nThe proceeds from the October 2024 offering were intended for the Phase 2a clinical trial for intranasal foralumab in non-active secondary progressive multiple sclerosis, expediting Alzheimer's disease development, and working capital.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTiziana Life Sciences Ltd (TLSA) - VRIO Analysis: NASDAQ Listing and Market Access\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eNASDAQ Listing and Market Access\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides access to deep US capital markets and lends credibility, as demonstrated by regaining compliance in \u003cstrong\u003eMarch 2025\u003c\/strong\u003e after a bid price issue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many small biotechs are listed on NASDAQ, but maintaining compliance is a baseline requirement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the listing itself is a regulatory hurdle that must be cleared, but the status is not a unique advantage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company successfully addressed the listing qualification issue, showing regulatory competence. The non-compliance notice was issued on \u003cstrong\u003eJanuary 29, 2025\u003c\/strong\u003e, and compliance was regained on \u003cstrong\u003eMarch 12, 2025\u003c\/strong\u003e, by maintaining a minimum closing bid price of \u003cstrong\u003e$1.00\u003c\/strong\u003e or more for at least ten consecutive trading days.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is table stakes for accessing the primary US investor base.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$199.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 2, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow (FCF)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$1.5m USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF 5-Year CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePast 5 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF Growth (Last Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Price Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMost recent rating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe planned IL-6 spinout involves the fully human anti-IL-6 receptor monoclonal antibody, \u003cstrong\u003eTZLS-501\u003c\/strong\u003e, with Tiziana shareholders retaining value via distribution in specie. This is contextualized by \u003cstrong\u003eNovartis' recent $1.4 billion acquisition of Tourmaline Bio\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek Ending\u003c\/td\u003e\n\u003ctd\u003eCash Inflow (Illustrative)\u003c\/td\u003e\n\u003ctd\u003eCash Outflow (Illustrative)\u003c\/td\u003e\n\u003ctd\u003eNet Cash Flow (Illustrative)\u003c\/td\u003e\n\u003ctd\u003eIL-6 Spinout Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1 (Friday)\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$500,000.00\u003c\/td\u003e\n\u003ctd\u003e-$500,000.00\u003c\/td\u003e\n\u003ctd\u003eLegal\/Advisory Fees Accrual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$450,000.00\u003c\/td\u003e\n\u003ctd\u003e-$450,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$400,000.00\u003c\/td\u003e\n\u003ctd\u003e-$400,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$350,000.00\u003c\/td\u003e\n\u003ctd\u003e-$350,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$300,000.00\u003c\/td\u003e\n\u003ctd\u003e-$300,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$250,000.00\u003c\/td\u003e\n\u003ctd\u003e-$250,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$200,000.00\u003c\/td\u003e\n\u003ctd\u003e-$200,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$150,000.00\u003c\/td\u003e\n\u003ctd\u003e-$150,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$100,000.00\u003c\/td\u003e\n\u003ctd\u003e-$100,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$50,000.00\u003c\/td\u003e\n\u003ctd\u003e-$50,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$50,000.00\u003c\/td\u003e\n\u003ctd\u003e-$50,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$50,000.00\u003c\/td\u003e\n\u003ctd\u003e-$50,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e$0.00\u003c\/td\u003e\n\u003ctd\u003e$50,000.00\u003c\/td\u003e\n\u003ctd\u003e-$50,000.00\u003c\/td\u003e\n\u003ctd\u003ePre-Spin Planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntranasal Foralumab Trial Status:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e10 patients\u003c\/strong\u003e with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) dosed in an Expanded Access (EA) Program (NCT06802328).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImprovement or stability of disease\u003c\/strong\u003e seen within 6 months in all 10 patients.\u003c\/li\u003e\n\u003cli\u003eFDA allowed an additional \u003cstrong\u003e20 patients\u003c\/strong\u003e to be enrolled in this EA program.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516265652373,"sku":"tlsa-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tlsa-vrio-analysis.png?v=1740224052","url":"https:\/\/dcf-model.com\/es\/products\/tlsa-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}